Relay Therapeutics’ Zovegalisib Delivers Strong Early Results in Rare Blood Vessel Disorder
Relay Therapeutics’ drug zovegalisib showed strong results in shrinking rare blood vessel disease lesions with good safety.
/ 4 items
#RLAY↓
FDA Grants Breakthrough Status to Zovegalisib for Advanced Breast Cancer
Relay Therapeutics' (RLAY) zovegalisib receives FDA Breakthrough Therapy designation for treating PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor treatment.
Oppenheimer Turns Bullish on Relay Therapeutics Ahead of Key Data
Oppenheimer upgrades Relay Therapeutics to Outperform, citing potential upside from competitor trial risks and upcoming VIKTORIA-1 results.
Wells Fargo Upgrades Relay Therapeutics and Zymeworks Stocks
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.